Prenetics Reports 480% Revenue Growth to $92.4 Million in 2025

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Feb 18 2026

0mins

PRE-3.47%

Should l Buy PRE?

Source: Newsfilter

Revenue Surge: In 2025, Prenetics reported a staggering 480% year-over-year revenue increase to $92.4 million, with Q4 revenue reaching $36.6 million, reflecting a 55% quarter-over-quarter growth, indicating strong market demand and expansion potential for the IM8 brand.
IM8 Brand Breakthrough: IM8 achieved $10 million in monthly revenue in December 2025, reaching an annualized recurring revenue (ARR) of $120 million, making it one of the fastest-growing brands in the global supplement industry, showcasing exceptional product-market fit and customer loyalty.
Strategic Transformation Completed: The company successfully completed its strategic transformation by divesting ACT Genomics and Insighta, resulting in approximately $171 million in adjusted liquidity with zero debt, thereby strengthening its financial foundation for future growth.
Optimistic Future Outlook: Prenetics anticipates IM8 revenue to reach between $180 million and $200 million in 2026, demonstrating robust growth potential, and aims to achieve adjusted EBITDA profitability by 2027, further solidifying its market leadership.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PRE?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PRE

About PRE

Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Prenetics Executives Invest $2.75 Million in Stock Purchases

20 hours agoNewsfilter

Executive Stock Purchases: Prenetics' executive leadership team executed open market purchases of 76,060 shares during the trading window from February 23 to 27, 2026, totaling approximately $1.3 million, demonstrating confidence in the company's future growth.
CEO Personal Investment: CEO Danny Yeung invested about $750,000 in this round, an increase from his previous investment of approximately $502,000 in November 2025, indicating his ongoing confidence in the performance of the IM8 business.
Strong Financial Performance: The IM8 brand achieved over $100 million in annualized recurring revenue within just 11 months of launch, making it one of the fastest-growing brands in consumer health, which further strengthens the company's competitive position in the market.
Strategic Implications: The continued investment by executives not only reflects their trust in the company's fundamentals but may also attract more investor attention to Prenetics, potentially driving the stock price upward and enhancing market confidence.

Prenetics Launches New Clinical-Grade Nutritional Supplement

Feb 23 2026Newsfilter

Product Upgrade: Prenetics has launched Daily Ultimate Essentials PRO, featuring a 733% increase in Vitamin B12 and a 150% increase in Vitamin K2, significantly enhancing cellular energy and bone health, marking a major advancement in nutritional science.
New Flavor Introduction: The new product introduces two flavors, Mango + Passionfruit and Lemon + Orange, catering to consumer demand for variety while maintaining the original price, thereby enhancing customer appeal.
Automatic Customer Upgrade: Existing IM8 subscribers will be automatically upgraded to the PRO formula with their next delivery at no extra cost, a strategy that not only boosts customer satisfaction but also strengthens brand loyalty.
Market Performance: The IM8 brand achieved over $100 million in annualized recurring revenue within just 11 months of launch, demonstrating strong growth potential in the global health market and further solidifying Prenetics' leadership in health sciences.

U.S. Stocks Rise, Nasdaq Gains Over 1%

Feb 18 2026Benzinga

Market Performance: U.S. stocks broadly rose on Wednesday, with the Nasdaq Composite gaining over 1% and the Dow up 0.57% to close at 49,814.98, indicating positive market sentiment and increased investor confidence.
Sector Dynamics: Energy stocks rose by 1.6% on Wednesday, reflecting optimistic expectations for energy demand, while real estate stocks fell by 1.2% on Tuesday, highlighting challenges faced by the sector amid market uncertainties.
Durable Goods Orders: U.S. durable goods orders fell by 1.4% month-over-month in December, contrasting sharply with a revised 5.4% gain in November, suggesting a potential slowdown in economic growth that could impact future consumer and investment decisions.
Commodity Markets: Oil prices increased by 4.2% to $64.93 per barrel, gold rose by 2.3% to $5,020.40, and silver climbed 6.2% to $78.120, indicating a rising demand for commodities as investors seek safe-haven assets.

Prenetics Reports Strong FY Results with Revenue Surge and Key Milestones

Feb 18 2026seekingalpha

Financial Highlights: Prenetics reported a FY GAAP EPS of -$3.79, missing estimates by $1.25, yet achieved revenue of $92.39 million, a staggering 479.6% year-over-year increase, surpassing expectations by $2.25 million, indicating robust market performance.
IM8 Revenue Milestone: IM8 reached $10 million in monthly revenue in December 2025, achieving a $120 million annual recurring revenue (ARR) milestone, showcasing its rapid growth potential in the consumer health brand sector.
Key Performance Indicators: Monthly revenue for Q4 2025 was $10 million, a 51% increase from Q3, with quarterly revenue at $27.4 million, up 59%, and total customer orders reaching 230,000, reflecting strong market demand and an expanding customer base.
Operational Efficiency Gains: Average order value increased from $102 to $133, a 31% rise, while maintaining a gross margin of 60%, indicating significant progress in enhancing customer value and operational efficiency.